other_material
confidence high
sentiment positive
materiality 0.80
Indivior provides FY2026 guidance: revenue $1.125B-$1.195B, Adj. EBITDA $535M-$575M
Indivior Pharmaceuticals, Inc.
- Total net revenue expected $1,125M-$1,195M; SUBLOCADE net revenue $905M-$945M.
- Non-GAAP operating expenses guided at $430M-$450M; adjusted EBITDA $535M-$575M.
- Completed Phase I of Indivior Action Agenda with annual operating expense savings of at least $150M.
- Shareholders approved U.K. to U.S. domicile change; expected effective Jan 26, 2026.
- Concluded DOJ matter by paying $295M in full; entered Phase II focused on accelerating growth.